| Authors |
Declared/Assessed Strategies |
Country and Date |
| Shafer RW et al. [26]
Dybul M et al. [50] |
Switching the classes of drugs as the first reaction to resistance and Applying resistance assays to avoid unnecessary drugs administration. |
USA, 2002- USA, 2002 |
| Clavel F et al. [4]
Cvetkovic RS et al. [51]
Di Giambendetto S et al. [52]
Shafer RW et al. [26] |
Applying new drugs, for salvage or rescue therapy, that can be achieved by using agents with increased potency or better pharmacokinetic properties or by using novel classes (i.e. fusion inhibitors) which are not susceptible to cross-resistance. |
France, 2004- New Zealand, 2003- Italy, 2009- USA, 2002 |
| Buendia P et al. [28] |
Predicting the development pathways of drug resistance with genotype-based prediction computer systems by using the patient’s clonal (pyro-) sequences at the beginning of therapy and failure points |
USA, 2009 |
| Ji H et al. [53] |
Selecting the best drug combination for national treatment programs by determining the prevalence of drug resistance mutations in both protease and reverse transcriptase inhibitors through using Pyro-sequencing |
Canada, 2010 |
| Yebra G et al. [36] |
Conducting specific drug resistance surveillance tools among immigrants in order to prevent probable therapeutic failures, especially to NNRTIs. |
Spain, 2011 |
| Trevino A et al. [54]
Imaz A et al. [55]
Tang MW et al. [56] |
Recommending not to apply commercial drug resistance tests before starting drug therapy, but to apply them at failure points, in order to increase the success rate of subsequent salvage therapy based on appropriate drug combination. |
Spain, 2011-Spain, 2012-USA, 2012 |
| Bercoff DP et al. [57] |
Identifying the component of viral genome which can potentially evolve resistance properties against an agent for determining the more vigorous therapeutic options |
Belgium, 2010 |
| Truong HM KT et al. [32]
Temereanca A EL et al. [[58]
Vercauteren J WA et al. [41]
Pingen M et al. [59] |
Using genotyping resistance testing in ARV-naïve HIV positive patients; in order to identify regimens with vigorous genetic barrier to prevent failure of first line therapy. |
Netherland, 2011-Europe and Israel, 2009-Romany, 2011-USA, 2011 |
